The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at a concentration of 1 - 5 µg/ml.
Note: This antibody is suitable for use in ELISA as a coating antibody. Immediately prior to use as a coating antibody in ELISA, dilute this preparation to a final concentration of 1 - 5 µg/mL, and use 100 µL to coat each well of a microtiter plate.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Released primarily from activated T lymphocytes.
In Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.
Belongs to the type II (or gamma) interferon family.
Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.